TrialThe Lancet. Oncology2021

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.

Fred Saad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.